Safety of guselkumab in hepatitis B virus infection

Duncan, J.R.; Orlowski, T.J.; Elewski, B.E.

Dermatology Online Journal 25(10)

2019


ISSN/ISBN: 1087-2108
PMID: 31735016
Document Number: 697786
Reactivation of hepatitis B virus (HBV) following the use of TNF antagonists has been reported and is a contraindication to use of these medications. Although the risk of reactivation of HBV during use of ustekinumab and secukinumab is low in patients with only HBV core antibody positivity, the risk is substantial in patients with chronic HBV infection. Less information is available regarding the use of pure IL-23 antagonists. Herein we discuss the successful treatment with guselkumab of a patient with HBV core antibody positivity, without evidence of HBV reactivation or other liver complications.

Document emailed within 1 workday
Secure & encrypted payments